| scholarly article | Q13442814 |
| P2093 | author name string | M J Robertson | |
| A Krishnan | |||
| A Goy | |||
| R I Fisher | |||
| E Epner | |||
| S Lonial | |||
| B S Kahl | |||
| H Shi | |||
| J P Leonard | |||
| S de Vos | |||
| B Djulbegovic | |||
| S H Bernstein | |||
| A L Boral | |||
| O A O'Connor | |||
| S Nasta | |||
| P2860 | cites work | A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma | Q28254924 |
| Biology and therapy of mantle cell lymphoma | Q30437744 | ||
| Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies | Q33345317 | ||
| Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma | Q33364240 | ||
| Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma | Q33364244 | ||
| Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity | Q33370812 | ||
| Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma | Q33372761 | ||
| Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group | Q33773306 | ||
| Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma | Q34815786 | ||
| Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries | Q35076617 | ||
| Mantle cell lymphoma: established therapeutic options and future directions | Q35605571 | ||
| Current treatment approaches for mantle-cell lymphoma | Q36254655 | ||
| Update on the molecular biology of mantle cell lymphoma | Q36364527 | ||
| Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. | Q37088576 | ||
| Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. | Q43963780 | ||
| Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur | Q45182734 | ||
| Treatment of myeloma--are we making progress? | Q46406844 | ||
| High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma | Q46788297 | ||
| A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma | Q46830943 | ||
| Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma | Q47741041 | ||
| A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150 | Q80258993 | ||
| Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib | Q83930160 | ||
| P433 | issue | 3 | |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| patient | Q181600 | ||
| mantle cell lymphoma | Q268713 | ||
| P304 | page(s) | 520-525 | |
| P577 | publication date | 2008-12-12 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study | |
| P478 | volume | 20 |
| Q46974416 | 'Use it again!': retherapy with bendamustine in indolent B-cell lymphoproliferative disorders |
| Q33399582 | A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma |
| Q34663617 | A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). |
| Q60922642 | A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma |
| Q33396522 | A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma |
| Q33394153 | A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). |
| Q33398818 | A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma |
| Q35604056 | Acquired STAT4 deficiency as a consequence of cancer chemotherapy |
| Q57048075 | Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States |
| Q51726930 | An Immunohistochemical Survey of SNARE Proteins Shows Distinct Patterns of Expression in Hematolymphoid Neoplasia. |
| Q30498194 | Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma |
| Q38382492 | Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma? |
| Q38948814 | Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies |
| Q37498829 | Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality |
| Q34478543 | Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model |
| Q38847015 | Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation. |
| Q33404090 | Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study |
| Q33394873 | Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma |
| Q90321401 | Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403 |
| Q93144918 | Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later |
| Q26738940 | Bortezomib for the treatment of mantle cell lymphoma: an update |
| Q36868056 | Bortezomib for the treatment of non-Hodgkin's lymphoma |
| Q36278006 | Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes |
| Q38582650 | Bortezomib in the treatment of mantle cell lymphoma |
| Q90158512 | Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial |
| Q36640837 | Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature |
| Q57214849 | Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma |
| Q33893704 | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies |
| Q35206717 | Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo |
| Q84797558 | Case report: blastic Mantle Cell Leukemia |
| Q88868446 | Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib |
| Q38110232 | Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. |
| Q35400933 | Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies |
| Q36837797 | Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen |
| Q38056761 | Current and emerging new treatment strategies for mantle cell lymphoma |
| Q30456545 | Current and emerging therapies in mantle cell lymphoma |
| Q41254748 | Current and emerging treatment options for mantle cell lymphoma |
| Q37044078 | Current approaches and advance in mantle cell lymphoma treatment |
| Q38224186 | Current regimens and novel agents for mantle cell lymphoma |
| Q37956405 | Current status of targeted therapies for mantle cell lymphoma |
| Q90183400 | Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma |
| Q33832937 | Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications |
| Q42153285 | Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 |
| Q38582791 | Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies |
| Q36349396 | Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study |
| Q45124918 | ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. |
| Q50025694 | Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the rand |
| Q61803981 | Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy |
| Q38055498 | Emerging agents for the treatment of mantle cell lymphoma |
| Q37598947 | Emerging therapies for B-cell non-Hodgkin lymphoma |
| Q33413598 | Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study |
| Q37598141 | Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies |
| Q36852277 | From bortezomib to other inhibitors of the proteasome and beyond |
| Q57812658 | Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymp |
| Q85213407 | Haematological cancer: Bortezomib in MCL--new standard of care or just another option? |
| Q39187610 | How to manage mantle cell lymphoma. |
| Q38183759 | Ibrutinib in B-cell Lymphomas |
| Q89529544 | Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy |
| Q51677133 | Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab. |
| Q38539956 | Inflammation and cancer: advances and new agents |
| Q36612648 | Initial therapy of mantle cell lymphoma |
| Q38939419 | Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done? |
| Q38098877 | Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? |
| Q44993089 | Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma? |
| Q38465626 | Lenalidomide for mantle cell lymphoma |
| Q33401684 | Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial |
| Q38926895 | Long term remission in a case of Plasmablastic lymphoma treated with COMP (Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone) and Bortezomib |
| Q46775765 | Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. |
| Q33410282 | Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study |
| Q92880602 | Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab |
| Q91752037 | Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma |
| Q30452150 | Management of Mantle Cell Lymphoma: Key Challenges and Next Steps |
| Q34360347 | Mantle cell lymphoma activation enhances bortezomib sensitivity |
| Q28075606 | Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents |
| Q36150574 | Mantle cell lymphoma of the larynx: Primary case report |
| Q38012084 | Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management |
| Q38165907 | Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management |
| Q38535489 | Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management |
| Q40126253 | Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management |
| Q37579294 | Mantle cell lymphoma: are current therapies changing the course of disease? |
| Q34568868 | Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era |
| Q28256317 | Mantle cell lymphoma: observation to transplantation |
| Q37622873 | Mantle cell lymphoma: state-of-the-art management and future perspective |
| Q44679554 | Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology |
| Q35127368 | Molecular targeted approaches in mantle cell lymphoma |
| Q26821766 | New molecular targets in mantle cell lymphoma |
| Q37918027 | New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice |
| Q57217007 | Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q43139321 | Non-Hodgkin's lymphoma in the elderly |
| Q36820885 | Non-Hodgkin's lymphomas, version 4.2014. |
| Q39431412 | Novel agents in indolent lymphomas. |
| Q38516704 | Novel agents in mantle cell lymphoma |
| Q39290199 | Novel agents in mantle cell lymphoma |
| Q37803308 | Novel therapeutic agents for B-cell lymphoma: developing rational combinations |
| Q35111768 | Novel therapeutics for aggressive non-Hodgkin's lymphoma |
| Q33405103 | Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study |
| Q43045261 | Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy |
| Q34788381 | Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. |
| Q37980900 | PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies |
| Q39695887 | PRDM1 is required for mantle cell lymphoma response to bortezomib |
| Q34465347 | Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study |
| Q34505392 | Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo |
| Q42954066 | Phase 1 trial of bortezomib plus R‐CHOP in previously untreated patients with aggressive non‐Hodgkin lymphoma |
| Q37636965 | Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). |
| Q35050501 | Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma |
| Q33394689 | Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. |
| Q40333043 | Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma |
| Q33390073 | Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition |
| Q46602218 | Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology |
| Q36456078 | Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. |
| Q34225158 | Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group |
| Q38568358 | Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? |
| Q38415946 | Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. |
| Q50128397 | Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma |
| Q38532268 | Prognosis and outcome of stem cell transplantation for mantle cell lymphoma |
| Q35989980 | Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside |
| Q36028745 | Proteasome inhibitors in mantle cell lymphoma |
| Q38017790 | Radioimmunotherapy in mantle cell lymphoma. |
| Q53730905 | Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment. |
| Q38844932 | Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. |
| Q35835983 | Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus? |
| Q43089411 | Selectively killing transformed cells through proteasome inhibition |
| Q50204389 | Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. |
| Q30358639 | Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. |
| Q34414702 | Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma |
| Q34413686 | Targeted therapy in lymphoma |
| Q37709559 | The development and pharmacology of proteasome inhibitors for the management and treatment of cancer |
| Q35475256 | The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma |
| Q37579296 | The future of small molecule inhibitors in lymphoma |
| Q55007581 | The molecular pathogenesis of mantle cell lymphoma. |
| Q39029195 | The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma |
| Q95650650 | The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges |
| Q39414811 | The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma |
| Q52648382 | The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma. |
| Q30248842 | The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. |
| Q26772907 | The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? |
| Q64121132 | Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead |
| Q36498968 | Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501) |
| Q48238170 | Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. |
| Q38584922 | Treatment options for mantle cell lymphoma. |
| Q52802238 | Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices. |
| Q56882990 | Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma |
| Q38345594 | Treatment strategies in mantle cell lymphoma |
| Q35146262 | Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma |
| Q28082910 | Trial Watch: Proteasomal inhibitors for anticancer therapy |
| Q51251017 | Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network. |
| Q53064495 | [Clinical analysis of the character and prognostic factors of 23 cases of mantle cell lymphoma]. |
Search more.